Serum irisin levels in women with polycystic ovary syndrome: a cross-sectional case-control study
Keywords:
Polycystic Ovary Syndrome, Myokines, Biomarkers, ROC Curve, Insulin Resistance, Hyperandrogenism, Adiposity, Rotterdam Criteria, Diagnostic ThresholdAbstract
BACKGROUND: Polycystic ovary syndrome (PCOS) is a common endocrine–metabolic disorder. Irisin is an exercise-related myokine involved in energy homeostasis; however, prior studies have reported inconsistent associations between irisin and PCOS.
OBJECTIVES: To compare serum irisin levels between women with PCOS and non-PCOS controls and to assess the discriminatory performance of irisin for PCOS.
DESIGN AND SETTING: Cross-sectional, case–control study conducted at a tertiary referral center.
METHODS: We enrolled 144 women, 72 with PCOS and 72 non-PCOS as controls. Serum irisin levels were measured using an enzyme-linked immunosorbent assay. Adjusted comparisons were performed using a general linear model, and the association between irisin and PCOS was further evaluated using multivariable binary logistic regression. Receiver operating characteristic (ROC) analysis was used to assess the diagnostic performance of irisin.
RESULTS: Serum irisin levels in the PCOS group were significantly lower than those in the control group (p = 0.006). In the age and body mass index (BMI) adjusted ANCOVA model, PCOS status remained significantly associated with lower log-transformed irisin (p = 0.002). In a multivariable logistic regression analysis adjusted for age and BMI, log-transformed irisin levels remained independently associated with PCOS (p = 0.006). In ROC analysis, the area under the ROC curve for irisin was 0.632; an irisin cut-off of ≤ 16.2 ng/mL resulted in 87.5% sensitivity and 38.89% specificity.
CONCLUSIONS: Women with PCOS had lower circulating irisin levels than controls, and this association persisted after adjusting for age and BMI. Discriminatory performance was modest, and specificity was low at the selected cutoff. Larger studies are warranted to validate these findings.
Downloads
References
1. Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016 Aug 11;2:16057. PMID: 27510637; https://doi.org/10.1038/nrdp.2016.57.
2. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the Polycystic Ovary Syndrome in Unselected Black and White Women of the Southeastern United States: A Prospective Study. J Clin Endocrinol Metab. 1998 Sep 1;83(9):3078–82. https://doi.org/10.1210/jcem.83.9.5090.
3. Abali R, Temel Yuksel I, Yuksel MA, et al. Implications of circulating irisin and Fabp4 levels in patients with polycystic ovary syndrome. Journal of Obstetrics and Gynaecology. 2016 Oct 2;36(7):897–901. PMID: 27184575; https://doi.org/10.3109/01443615.2016.1174200.
4. Zore T, Joshi NV, Lizneva D, Azziz R. Polycystic Ovarian Syndrome: Long-Term Health Consequences. Semin Reprod Med. 2017 May;35(3):271–81. https://doi.org/10.1055/s-0037-1603096.
5. De Wilde MA, Lamain-de Ruiter M, Veltman-Verhulst SM, et al. Increased rates of complications in singleton pregnancies of women previously diagnosed with polycystic ovary syndrome predominantly in the hyperandrogenic phenotype. Fertility and Sterility. 2017 Aug;108(2):333–40. https://doi.org/10.1016/j.fertnstert.2017.06.015.
6. Aydin S. Three new players in energy regulation: Preptin, adropin and irisin. Peptides. 2014 Jun;56:94–110. https://doi.org/10.1016/j.peptides.2014.03.021.
7. Korta P, Pocheć E, Mazur-Biały A. Irisin as a Multifunctional Protein: Implications for Health and Certain Diseases. Medicina. 2019 Aug 15;55(8):485. https://doi.org/10.3390/medicina55080485.
8. Huh JY, Panagiotou G, Mougios V, et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism. 2012 Dec;61(12):1725–38. https://doi.org/10.1016/j.metabol.2012.09.002.
9. Cai X, Qiu S, Li L, Zügel M, Steinacker JM, Schumann U. Circulating irisin in patients with polycystic ovary syndrome: a meta-analysis. Reproductive BioMedicine Online. 2018 Feb;36(2):172–80. https://doi.org/10.1016/j.rbmo.2017.10.114.
10. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction. 2004 Jan 1;19(1):41–7. https://doi.org/10.1093/humrep/deh098.
11. Wang J, Wu D, Guo H, Li M. Hyperandrogenemia and insulin resistance: The chief culprit of polycystic ovary syndrome. Life Sciences. 2019 Nov;236:116940. https://doi.org/10.1016/j.lfs.2019.116940.
12. Sahmay S, Aydogan Mathyk B, et al. Serum AMH levels and insulin resistance in women with PCOS. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2018 May;224:159–64. https://doi.org/10.1016/j.ejogrb.2018.03.007.
13. Cunningham AT, Crittendon DR, White N, Mills GD, Diaz V, LaNoue MD. The effect of diabetes self-management education on HbA1c and quality of life in African-Americans: a systematic review and meta-analysis. BMC Health Serv Res. 2018 Dec;18(1):367. https://doi.org/10.1186/s12913-018-3186-7.
14. Kopin L, Lowenstein CJ. Dyslipidemia. Ann Intern Med. 2017 Dec 5;167(11):ITC81–96. https://doi.org/10.7326/AITC201712050.
15. Amiri S, Behnezhad S. Obesity and anxiety symptoms: a systematic review and meta-analysis. Neuropsychiatr. 2019 Jun;33(2):72–89. https://doi.org/10.1007/s40211-019-0302-9.
16. Wang W, Guo Y, Zhang X, Zheng J. Abnormal irisin level in serum and endometrium is associated with metabolic dysfunction in polycystic ovary syndrome patients. Clinical Endocrinology. 2018 Oct;89(4):474–80. https://doi.org/10.1111/cen.13805.
17. Adamska A, Karczewska-Kupczewska M, Lebkowska A, et al. Serum irisin and its regulation by hyperinsulinemia in women with polycystic ovary syndrome. Endocr J. 2016;63(12):1107–12. https://doi.org/10.1507/endocrj.EJ16-0249.
18. Gao S, Cheng Y, Zhao L, Chen Y, Liu Y. The relationships of irisin with bone mineral density and body composition in PCOS patients. Diabetes Metabolism Res. 2016 May;32(4):421–8. https://doi.org/10.1002/dmrr.2767.
19. Pukajło K, Łaczmański Ł, Kolackov K, et al. Irisin plasma concentration in PCOS and healthy subjects is related to body fat content and android fat distribution. Gynecological Endocrinology. 2015 Nov 2;31(11):907–11. https://doi.org/10.3109/09513590.2015.1065482.
20. Patti ME, Butte AJ, Crunkhorn S, et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad Sci USA. 2003 Jul 8;100(14):8466–71. https://doi.org/10.1073/pnas.1032913100.
21. Skov V, Glintborg D, Knudsen S, et al. Reduced Expression of Nuclear-Encoded Genes Involved in Mitochondrial Oxidative Metabolism in Skeletal Muscle of Insulin-Resistant Women With Polycystic Ovary Syndrome. Diabetes. 2007 Sep 1;56(9):2349–55. https://doi.org/10.2337/db07-0275.
22. Yildiz BO, Knochenhauer ES, Azziz R. Impact of Obesity on the Risk for Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism. 2008 Jan 1;93(1):162–8. https://doi.org/10.1210/jc.2007-1834.
23. Bostancı MS, Akdemir N, Cinemre B, Cevrioglu AS, Özden S, Ünal O. Serum irisin levels in patients with polycystic ovary syndrome. Eur Rev Med Pharmacol Sci. 2015 Dec 1;19(23):4462–8. PubMed PMID: 26698239.
24. Bastu E, Zeybek U, Gurevin EG, et al. Effects of Irisin and Exercise on Metabolic Parameters and Reproductive Hormone Levels in High-Fat Diet-Induced Obese Female Mice. Reprod Sci. 2018 Feb;25(2):281–91. https://doi.org/10.1177/1933719117711264.
25. Qiu S, Cai X, Sun Z, Schumann U, Zügel M, Steinacker JM. Chronic Exercise Training and Circulating Irisin in Adults: A Meta-Analysis. Sports Med. 2015 Nov;45(11):1577–88. https://doi.org/10.1007/s40279-014-0293-4.
26. Abazar E, Taghian F, Mardanian F, Forozandeh D. Effects of aerobic exercise on plasma lipoproteins in overweight and obese women with polycystic ovary syndrome. Adv Biomed Res. 2015;4(1):68. https://doi.org/10.4103/2277-9175.153892.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Atahan Toyran, Yagmur Minareci, Cavidan Gulerman
This work is licensed under a Creative Commons Attribution 4.0 International License.
